Browse articles from EyeWorld.org related to dry eye. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Twelve-month results for Phase 2 trial evaluating heat-therapy system for MGD ➤ Topline results from targeted photobiomodulation for treatment of progressive myopia ➤ Enrollment complete in Phase 3 trials to evaluate new wet AMD therapy ➤ ‘Low tech’ way to prioritize cataract surgery ➤ ASCRS news and events
➤ Topline results for investigational first-in-class dry eye drop ➤ Dosing complete in second cohort of Stargardt disease gene therapy trial ➤ Enrollment complete for Phase 2 acute optic neuritis trial ➤ Enrollment complete for Phase 1/2a trial evaluating neovascular AMD therapy ➤ ASCRS news and events
➤ One-year data from first-in-human drug eluting IOL ➤ Company begins two Phase 2 studies for glaucoma treatment ➤ First patient dosed in allogenic cell therapy trial ➤ Company outlines resubmission plan for reproxalap NDA ➤ Safety information for the upcoming solar eclipse ➤ Upcoming company presentations at Eyecelerator and the ASCRS Annual Meeting ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Positive topline results in trial for retinitis pigmentosa treatment ➤ Phase 2 trial for first-in-human inflammatory dry eye therapy ➤ Landmark clinical trial shows non-inferiority of Nanodropper technology ➤ Dosing complete for gene therapy aiming to help patients with Leber congenital amaurosis ➤ Enrollment begins for secondary IOL technology Phase 1 pivotal trial ➤ Strategic alignment news ➤ ASCRS news and events
➤ Phase 3 clinical trial for water-free dry eye cyclosporine drop ➤ Phase 2b results for drug-eluting contact lens for glaucoma ➤ Dosing continues for Phase 1/2 trial evaluating gene therapy for X-linked retinoschisis ➤ Higher dose, extended wet AMD treatment non-inferior to standard of care ➤ Study: AI detects severe retinopathy of prematurity with 100% accuracy ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ FDA approves new drug for postop inflammation and pain ➤ Primary endpoints in unadjusted population not met in Phase 3 trial for dry eye drop ➤ Study links inherited eye diseases to gut bacteria ➤ Acquisitions and other news ➤ ASCRS news and events
➤ FDA approves new excimer laser technology ➤ Phase 3 trial to evaluate phentolamine for treatment of decreased visual acuity ➤ Phase 2 trial of investigational dry eye drug sees effect on signs and symptoms ➤ Study has new findings to promote corneal healing ➤ ASCRS news and events
➤ ASCRS advocacy helps protect MIGS coverage ➤ FDA approves generic loteprednol etabonate ophthalmic suspension ➤ Orphan Drug Designation granted for corneal endothelial cell substitute ➤ Positive results in Phase 2 clinical trial for contact lens discomfort ➤ First patient visits ➤ Acquisition news ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Positive topline results in Phase 2a trial for treatment of MGD in patients with Demodex ➤ First patient visit in Phase 2b trial evaluating anti-TNFα for dry eye disease ➤ Smart contact lens makes progress ➤ Asset transition ➤ ASCRS news and events
Explaining the nuances of dry eye and available treatment options to patients can be a challenge, especially when it comes to asymptomatic patients. Two doctors discussed how they explain the different types of dry eye and how they talk about available treatment options.